Profile data is unavailable for this security.
About the company
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.
- Revenue in USD (TTM)0.00
- Net income in USD-31.08m
- Incorporated2007
- Employees25.00
- LocationCognition Therapeutics IncSuite 261, 2403 Sidney StreetPITTSBURGH 15203United StatesUSA
- Phone+1 (412) 770-1621
- Fax+1 (302) 697-4597
- Websitehttps://cogrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palatin Technologies, Inc. | 5.90m | -32.20m | 20.65m | 34.00 | -- | 13.08 | -- | 3.50 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Biora Therapeutics Inc | 860.00k | -86.81m | 21.41m | 58.00 | -- | -- | -- | 24.90 | -5.57 | -5.56 | 0.024 | -2.49 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 21.67m | 42.00 | -- | 1.40 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 22.76m | 46.00 | -- | 1.22 | -- | 1.09 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Hcw Biologics Inc | 3.92m | -38.37m | 23.19m | 45.00 | -- | -- | -- | 5.91 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -31.08m | 23.26m | 25.00 | -- | 1.01 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 11.17m | -66.17m | 23.65m | 100.00 | -- | 0.2754 | -- | 2.12 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Iterum Therapeutics PLC | 0.00 | -28.34m | 23.95m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Unity Biotechnology Inc | 0.00 | -27.86m | 24.43m | 19.00 | -- | 1.24 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 24.66m | 50.00 | -- | -- | -- | 24.42 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Geovax Labs Inc | 300.68k | -26.92m | 24.74m | 17.00 | -- | -- | -- | 82.28 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -12.20m | 24.76m | 6.00 | -- | -- | -- | -- | -0.6924 | -0.6924 | 0.00 | -0.1201 | 0.00 | -- | -- | 0.00 | -839.15 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | -- | -- | -- | -- | 26.85 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.88m | 25.31m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 25.49m | 53.00 | -- | 1.18 | -- | 3.07 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Nuo Therapeutics Inc | 1.03m | -2.69m | 25.63m | -- | -- | 41.78 | -- | 24.92 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Lipocine Inc | 4.80m | -8.49m | 25.88m | 17.00 | -- | 1.22 | -- | 5.39 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Cognition Therapeutics Inc's reporting currency: US Dollar USD
9.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 909.05k | 2.27% |
| AWM Investment Co., Inc.as of 31 Mar 2024 | 650.00k | 1.62% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 500.00k | 1.25% |
| Timelo Investment Management, Inc.as of 31 Mar 2024 | 480.68k | 1.20% |
| AIGH Capital Management LLCas of 30 Jun 2024 | 300.77k | 0.75% |
| Corsair Capital Management LPas of 31 Mar 2024 | 285.00k | 0.71% |
| Geode Capital Management LLCas of 30 Jun 2024 | 244.77k | 0.61% |
| Carlson Capital LPas of 31 Mar 2024 | 214.00k | 0.53% |
| American Money Management Corp.as of 30 Jun 2024 | 205.00k | 0.51% |
| CM Management LLCas of 30 Jun 2024 | 200.00k | 0.50% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
